A systematic review of the safety information contained within the Summaries of Product Characteristics of medications licensed in the United Kingdom for Attention Deficit Hyperactivity Disorder. how does the safety prescribing advice compare with national guidance?

Email this article to a friend

Nicola Savill^* and Chris J Bushe

Child and Adolescent Psychiatry and Mental Health 2012, 6:2 doi:10.1186/1753-2000-6-2